Chronic central neuropathic pain after central nervous system injuries remains refractory to therapeutic interventions. A novel approach would be to target key intracellular signaling proteins that are known to contribute to continued activation by phosphorylation of kinases, transcription factors, and/or receptors that contribute to changes in membrane excitability. We demonstrate that one signaling kinase, calcium/ calmodulin-dependent kinase II (CaMKII), is critical in maintaining aberrant dorsal horn neuron hyperexcitability in the neuropathic pain condition after spinal cord injury (SCI). After contusion SCI at spinal level T10, activated CaMKII (phosphorylated, pCaMKII) expression is significantly upregulated in the T7/8 spinal dorsal horn in neurons, but not glial cells, and in oligodendrocytes in the dorsal column in the same rats that displayed at-level mechanical allodynia. Furthermore, identified spinothalamic neurons demonstrated significant increases of pCaMKII after SCI compared to sham-treated control animals. However, neither astrocytes nor microglia showed pCaMKII expression in either sham-treated or SCI rats. To demonstrate causality, treatment of SCI rats with KN-93, which prevents CaMKII activation, significantly attenuated at-level mechanical allodynia and aberrant wide dynamic range neuronal activity evoked by brush, pressure, and pinch stimuli and a graded series of von Frey stimuli, respectively. Persistent CaMKII activation contributes to chronic central neuropathic pain by mechanisms that involve maintained hyperexcitability of wide dynamic range dorsal horn neurons. Furthermore, targeting key signaling proteins is a novel, useful therapeutic strategy for treating chronic central neuropathic pain.
Introduction
Over 70% of people with spinal cord injury (SCI) suffer intractable and chronic central neuropathic pain (CNP) [ A novel mechanism of CNP after SCI is activation of intracellular signaling cascades in the spinal dorsal horn [11, 12] , similar to those that result in hippocampal long-term potentiation (LTP), which may contribute to neuropathic pain [27, 47, 55] . In LTP, glutamate receptor-mediated activation of a number of intracellular signaling kinases lead to increased mitogen activated protein kinases (MAPKs; eg, ERK1/2, p38 MAPK) and phosphorylation of transcription factors such as cAMP responsive element binding protein (CREB) and Elk-1 [28,31,33]. Activation of MAPK signaling pathways and CREB after peripheral injection of chemical irritants (eg, formalin, capsaicin) or peripheral nerve injury [34,36,37] are linked indirectly to central sensitization, a persistent increase in electrophysiological activity (background and to evoked stimuli) of spinal dorsal horn neurons. We previously reported increases in spinal levels of the phosphorylated (and thus activated) forms of the MAPKs, extracellular signal-related kinase (ERK)-1/2 and p38 MAPK, and the transcription factor CREB in SCI rats experiencing at-level mechanical allodynia [11, 12] . However, upstream signaling pathways that lead to the spinal LTP-like pathways after SCI are not known.
A critical key signaling molecule in LTP is calcium/calmodulindependent protein kinase II (CaMKII), a molecule phosphorylated through IP3 pathways initiated by glutamate receptor activation, which regulates calcium signaling, influences synaptic function by phosphorylation of membrane receptors, and is an important
